Dapagliflozin reduces pulmonary vascular damage and susceptibility to atrial fibrillation in right heart disease.
Dapagliflozin降低右心疾病肺血管損傷和易感性對心房顫動的影響。
ESC Heart Fail 2023-02-01
Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors on Outcomes After Catheter Ablation for Atrial Fibrillation.
鈉葡萄糖共同轉運蛋白2抑制劑對心房顫動導管消融術後結果的功效。
JACC Clin Electrophysiol 2023-03-10
Combined Minimally Invasive Surgical and Percutaneous Catheter Ablation of Atrial Fibrillation: JACC Review Topic of the Week.
心房纖維性的結合微創手術和經皮導管消融治療:JACC本週評論專題。
J Am Coll Cardiol 2023-04-03
Rationale and design of a randomized trial of the dapagliflozin evaluation on atrial fibrillation patients followed Cox-Maze IV: the DETAIL-CMIV study.
該研究的標題翻譯為:「Dapagliflozin評估對隨後接受Cox-Maze IV手術的房顫患者的隨機試驗的理據和設計:DETAIL-CMIV研究」。
Europace 2024-01-15
Inhibition of the K<sub>Ca</sub>2 potassium channel in atrial fibrillation: a randomized phase 2 trial.
房顫中K<sub>Ca</sub>2鉀通道的抑制:一項隨機2期試驗。
Nat Med 2024-02-10
Efficacy of dapagliflozin in improving arrhythmia-related outcomes after ablation for atrial fibrillation: a retrospective single-center study.
達帕格列酮在心房顫動消融後改善心律失常相關結果的功效:一項單中心的回顧性研究。
Clin Res Cardiol 2024-02-15
Pulmonary Vein Isolation With or Without Left Atrial Appendage Ligation in Atrial Fibrillation: The aMAZE Randomized Clinical Trial.
房顫患者的肺靜脈隔離術:aMAZE隨機臨床試驗中左心房附加部位結紮的應用。
JAMA 2024-04-04
Evaluation of the effect of empagliflozin on prevention of atrial fibrillation after coronary artery bypass grafting: a double-blind, randomized, placebo-controlled trial.
冠狀動脈旁路移植術後 empagliflozin 預防心房纖維顫動效果的評估:雙盲、隨機、安慰劑對照試驗。
Naunyn Schmiedebergs Arch Pharmacol 2024-07-02
Impact of Sodium-glucose Cotransporter 2 Inhibitor on Recurrence and Cardiovascular Outcomes after Catheter Ablation for Atrial Fibrillation in Patients with Heart Failure.
鈉-葡萄糖共轉運蛋白 2 抑制劑對心衰竭患者經導管消融治療心房顫動後復發及心血管結果的影響。
Heart Rhythm 2024-08-21
Potassium Supplementation and Prevention of Atrial Fibrillation After Cardiac Surgery: The TIGHT K Randomized Clinical Trial.
心臟手術後鉀補充與預防心房顫動:TIGHT K 隨機臨床試驗。
JAMA 2024-08-31